



BIODIEM LTD
ABN 20 096 845 993
Level 4,
100 Albert Road,
South Melbourne, Victoria, 3205
Australia
Phone: +613 9692 7240
Web: www.biodiem.com

Announcement

Company Update and EOFY 2017 Information

Melbourne, 10 July 2017: Infectious disease therapy and vaccine development company BioDiem Ltd and its subsidiary company Opal Biosciences Ltd are pleased to provide the following information.

Progress of Opal-T in antimicrobial studies

In laboratory testing Opal-T gel has shown antimicrobial activity against **methicillin-resistant *Staph aureus*** (Golden Staph; MRSA). This bacterium is responsible for mild to severe infections, from boils and abscesses to life threatening meningitis, bone or lung infections. Antibiotic-resistant infections can be difficult to treat. Opal-T gel has also shown activity against ***Neisseria gonorrhoea***, a bacterium responsible for causing the sexually-transmitted disease, gonorrhoea. Rising reports of antibiotic resistance to gonorrhoea are concerning health authorities worldwide. Opal-T gel will be tested in preclinical models of infection in the next few months.

EOFY Share Price information

For EOFY 2017 valuation purposes, the last sale price of

BDM ordinary shares = \$0.08
BDM preference shares = \$0.08
Opal Biosciences ordinary shares = \$0.20.

Shareholder Information at Share Registry, Computershare.

Shareholders are asked to ensure their contact details/ email addresses are up-to-date at Computershare. This can be done online via the Computershare Investor Centre (www.computershare.com.au).

- ENDS -

About BioDiem Ltd (www.biodiem.com)

BioDiem is an Australian biopharmaceutical company focused on developing and commercialising vaccines and infectious disease therapies. BioDiem's business model is to generate income from partnerships including with other vaccine and infectious disease treatment companies through existing and new licences to its LAIV vaccine and other technologies. Income comes from licence fees and royalties on sales.

BioDiem's lead technology is the LAIV (Live Attenuated Influenza Virus) vaccine technology used for production of seasonal and pandemic influenza vaccines and is given intranasally. This technology is licensed currently to two commercial partners, in India and China, and is licenced to the World Health Organisation as part of the Global Pandemic Influenza Action Plan to Increase Vaccine Supply. Serum Institute of India's Nasovac-S™ is based on BioDiem's technology and is already marketed in India. BioDiem's antimicrobial technology, BDM-I, is being developed through its subsidiary, Opal Biosciences Ltd.

About Opal Biosciences Ltd (www.opalbiosciences.com)

Opal Biosciences is an Australian biotechnology company and an innovative player in infectious disease treatment. The unmet need for new anti-infectives is due to increasing resistance to existing antibiotics, more widespread and common difficult-to-treat infections, and the paucity of upcoming new treatments. This need has spurred the EU and US to introduce significant financial incentives to encourage development of new anti-infectives. Opal is currently seeking funding to support the next stage of development of its products: Opal-I, an injectable product, and Opal-T, which can be applied to the skin.

Further information

Julie Phillips, Chief Executive Officer, BioDiem Ltd

Phone +61 3 9692 7222

Email jphillips@biodiem.com

Twitter [@biodiem](https://twitter.com/biodiem) [@opalbiosciences](https://twitter.com/opalbiosciences)